What Are MoVes? A New Class of Vesicles That Carry a Migrating Cancer Cell’s Genome
In this article
What Are MoVes? A New Class of Vesicles That Carry a Migrating Cancer Cell’s Genome
A study published in Nature Cell Biology on 28 October 2026 describes a new class of extracellular vesicles, 2–5 µm in size, that break off from the rear end of migrating cancer cells: “MoVes” (motile vesicles). According to the researchers, these vesicles carry the genome of mouse breast cancer cells, together with its somatic mutations. The finding draws attention because it touches the future direction of tests based on tumor DNA in the blood (ctDNA and liquid biopsy (in Turkish)). But the study rests on cell culture and mouse experiments; it contains no data showing that MoVes were detected in patient blood or that they can be used as a test. This article does not interpret anyone’s report or treatment: decisions about your own treatment and follow-up plan are made by the oncology physicians who follow you.
- What are MoVes? A class of extracellular vesicles, 2–5 µm in size, that break off from the rear end of a migrating cancer cell. An extracellular vesicle is a small membrane-bound sac that a cell releases outward.
- What is new? These vesicles carry not only proteins or short DNA fragments but the parent cell’s genome and somatic mutations, as well as RNA, organelles and mitochondria.
- Can they be used as a liquid biopsy? Not yet known. The study does not show this as a validated test in patient blood; the authors also state that it needs to be confirmed in animal models and in patients.
- Level of evidence: Mainly cell culture; the mouse experiments only look at the distribution of vesicles injected from outside. There are no patient data.
What are MoVes?
MoVes is short for “motile vesicles.” According to the study, these are large vesicles that form when the rear end of a cancer cell retracts while it moves in a mesenchymal manner, and that are left behind. The authors define them as a separate class from other groups of extracellular vesicles in terms of ultrastructure, molecular composition and sedimentation behavior.
| Topic | Detail |
|---|---|
| Size | 2–5 µm; they have a double-layered lipid membrane and often contain smaller vesicles inside |
| Where do they break off? | From the rear end of a migrating cancer cell; shown by live imaging and scanning electron microscopy |
| Which cells produce them? | Mouse 4T1, human MDA-MB-231 and MCF7 breast cancer cells and other cancer cell lines; cancer-associated fibroblasts |
| Non-cancer cells? | Never seen in the non-cancer breast epithelial line MCF10A; rare in other non-cancer cells |
| What do they carry? | Genomic DNA, RNA, organelles (mitochondria, lysosomes, endoplasmic reticulum, Golgi), EMT-associated proteins |
| Number per cell | 1–2 MoVes |
Source: Tsering et al., Nature Cell Biology, published online 28 October 2026 (DOI 10.1038/s41556-026-02097-2).
Figure 1 · The chain proposed by the study
From movement to vesicle release: what is left around the cell
How do MoVes differ from other groups of vesicles?
The same study also examined small vesicles (average 177 nm) and large vesicles (average 313 nm); MoVes differed from them in size, protein content and the way their DNA is protected. Because other large vesicle types that form during movement are also known (such as migrasomes and blebbisomes), what sets MoVes apart is not a single feature but the combination of features taken together.
Reduction of DNA after DNase I treatment
Percent. The smaller the reduction, the more of the DNA was protected inside the vesicle.
DNase I breaks down DNA that lies outside the vesicle. A smaller reduction in MoVes suggests that more of the DNA is protected inside the membrane. These measurements were made on vesicles obtained from mouse 4T1 cells.
What does “the entire genome” mean?
The researchers examined the DNA of MoVes isolated from mouse 4T1 breast cancer cells by whole-genome sequencing (WGS). As reported, the vesicle DNA carries the parent cell’s genome together with its somatic mutations, and its copy-number profile matches the parent cell. For how such sequencing methods are used in oncology, see our article on next-generation sequencing (NGS) (in Turkish).
| Finding | What was reported? |
|---|---|
| Mutated genes captured | Trp53, Pik3cg, Kit and Brca2; all four were found in both the vesicle DNA and the cell DNA |
| Confirmation | The Trp53 and Kit (A942S) changes were confirmed by Sanger sequencing and droplet digital PCR (ddPCR) |
| Copy number | The copy-number profile of the vesicle DNA is consistent with the parent cell |
| Other contents | Double-stranded DNA, histones, ribosomal RNA and BrdU-labeled (replicated) DNA |
Genome sequencing was done on vesicles obtained from mouse 4T1 cells; gene names are written in mouse gene nomenclature.
The phrase “the entire genome” refers here to laboratory vesicles from a mouse cell line. It has not been shown that MoVes in a patient’s blood would give the same result. Tests based on circulating tumor DNA today look at DNA fragments in a blood sample; what MoVes might add to these tests is not yet known.
Protein, organelle and mitochondrial cargo
In mass spectrometry, a total of 705 proteins were identified across the vesicles; 46 of them were enriched in MoVes. Proteins linked to adhesion and movement, such as integrins (β1, α6, αV), fibronectin, CD147 and myoferlin, stood out in MoVes, as did FAM3C, a protein that triggers EMT. Mitochondria, lysosomes, endoplasmic reticulum and Golgi were shown by electron microscopy and immunofluorescence.
The mitochondrial cargo was functional in recipient cells: 4T1 cells with partially reduced mtDNA took up MoVes-associated mitochondria, and 1 µg of MoVes increased basal and maximal oxygen consumption and ATP-linked respiration. In other words, MoVes-associated mitochondria were able to increase oxidative phosphorylation (OxPhos) in recipient cells. This finding was obtained in cultured cells.
How do MoVes form? The EMT link
Five drugs targeting actin, dynamin, ROCK and myosin II reduced both cell migration by about 65–75% and MoVes formation. GW4869, which blocks the formation of small vesicles, affected neither migration nor MoVes. The authors propose a model in which early initiation depends on actin polymerization and release depends on myosin II contraction and ROCK.
Cell movement after EMT induction (MCF10A)
Non-cancer cells were kept in EMT-inducing medium for 10 days. Movement speed, µm/min.
The same induction led to MoVes formation in MCF10A cells. The TGFβR1 inhibitor LY-364947, in turn, completely blocked the release of MoVes and vesicle DNA in 4T1 and MDA-MB-231 cells.
What did the mouse experiments show?
The mouse experiments in the study do not show that cancer spreads through MoVes; they look at where vesicles injected from outside go in the body.
| Topic | What was reported? |
|---|---|
| Setup | Injection into immunosuppressed NSG mice; imaging at 6 and 12 hours |
| Distribution | All vesicle types accumulated mainly in the liver; MoVes were taken up by Kupffer cells (F4/80 positive) |
| High dose | 20 µg of MoVes caused severe respiratory distress and loss of life in the mice within minutes of injection, with heavy accumulation in the lungs; large vesicles at the same dose did not do this |
This result concerns isolated vesicles injected into mice at a high dose; nothing can be inferred for humans. Clearance, organ tropism and safety thresholds were not examined.
Figure 2 · From the laboratory to patient blood: where we stand
Steps that have been done and steps not yet done
What could this mean for liquid biopsy?
Liquid biopsy is the general name for tests that look at tumor-derived DNA in the blood; for tissue biopsy, see our article What is a biopsy? (in Turkish). Because MoVes carry the parent cell’s mutation map, they could in the future give rise to the idea of a biomarker based on vesicle DNA in the blood. In the press release as well, the authors mention this as a possibility that could become real if confirmed in animal models and in patients.
| Question | At present |
|---|---|
| Have MoVes been detected in patient blood? | This study has no patient data |
| Has a test measured in blood been developed? | No |
| Do MoVes drive the spread of cancer? | Not yet determined |
| Would they replace existing ctDNA tests? | Unknown |
Source: the Nature Cell Biology paper and the press release of the McGill University Health Centre (MUHC) Research Institute.
Limits of this study
- Most of the study was done in cell culture, mainly in mouse 4T1 and human MDA-MB-231 cells.
- Many experiments rest on 3 biological replicates.
- This study includes no patient samples or data from patients.
- It has not been determined whether MoVes drive cancer progression; the mechanisms of their formation are still being investigated.
- The role of dynamin in MoVes release has not been settled; drugs such as Dynasore may have off-target effects.
- Silencing MYH10 (myosin IIB) did not noticeably change MoVes; the contraction mechanism is not fully defined.
- Telling MoVes apart from the other large vesicle types formed during movement rests on more than one feature.
Common misunderstandings
- “A test that measures MoVes in the blood has come out.” No. The study is cell culture and mouse data; there is no validated test in patient blood.
- “Vesicle DNA shows the whole tumor.” This was shown in a mouse cell line in the laboratory; it was not shown in a patient.
- “MoVes have been proven to cause cancer to spread.” No. The researchers say this has not yet been determined.
- “This finding has changed existing ctDNA tests.” No. The tests used today are not affected by this study; your physician interprets your results.
What does this news mean for you?
- This study does not change your treatment or follow-up plan; it is a discovery at the research stage.
- Ask the oncology physician who follows you about anything you wonder about blood tests or liquid biopsy.
- When you hear news of a new test, ask whether it has been validated with patient data.
For this article we did not check access to liquid biopsy or vesicle-based tests in centers in Turkey, or licensing and reimbursement conditions; we made no assumptions on these points. For broader information, see our article on ctDNA and liquid biopsy (in Turkish).
DROZDOGAN Academy Assessment
The MoVes study is a basic cell biology finding that makes it harder to think of cell migration merely as “a cell going from one place to another.” Its real clinical meaning depends on whether it will be tested in patient samples.
⚡ Why it matters
That a migrating cell leaves behind a large vesicle carrying a genome and organelles opens a new question about how cancer communicates with its surroundings. That it touches the field of liquid biopsy raises the interest further; but this assessment is ours.
✅ What is strong
The findings are supported by several methods: live imaging, electron microscopy, proteomics, genome sequencing, and confirmation by Sanger and ddPCR. There are also comparisons with non-cancer cells and experiments in which formation was controlled by drug interventions.
⚠️ What is weak
Genome sequencing was done in a mouse cell line; there are no patient data; many experiments rest on 3 replicates. The mouse experiment measures the distribution of vesicles injected from outside. We could not read the discussion of the paper in full.
🩺 Practical meaning for patients and physicians
There is no practical change today. For physicians and patients the real question is whether MoVes can be detected in patient blood or tumor tissue, and whether that would add anything to diagnosis or follow-up.
❓ Open questions
Are MoVes present in human tumors and in patient blood? In which tumor types and how often? Do they contribute to the spread of cancer? Would vesicle DNA add anything to existing ctDNA tests? None of these questions is answered by this study.
Conclusion: MoVes are an interesting laboratory finding showing that migrating cancer cells leave behind a new class of vesicles that carry a genome; they open a possibility for liquid biopsy but are not a test. No diagnostic or treatment decision should be based on this finding; discuss everything about your own situation with the physician who follows you.
Frequently asked questions
- What are MoVes?
- A class of extracellular vesicles, 2–5 µm in size, that break off from the rear end of migrating cancer cells and carry a genome, RNA and organelles.
- Can MoVes be measured in my blood?
- There is no such test at present. The study does not show that MoVes were detected in patient blood.
- Does vesicle DNA really carry the parent cell’s genome?
- In vesicles obtained from mouse 4T1 cells, whole-genome sequencing showed the somatic mutations of the parent cell; the Trp53 and Kit changes were also confirmed by Sanger and ddPCR. This has not been shown in patients.
- Do MoVes cause cancer to spread?
- This has not yet been determined. The researchers say it needs to be tested in separate studies.
- What is the difference between MoVes and ctDNA?
- ctDNA is tumor-derived DNA fragments circulating in the blood. MoVes are large vesicles left behind by a moving cell and carry a genome and organelles. What MoVes would add to ctDNA tests is unknown.
- What does the respiratory distress seen in mice mean for humans?
- Nothing can be inferred. It was seen with isolated vesicles injected into mice at a high dose.
Glossary
- MoVes
- “Motile vesicles”; 2–5 µm vesicles that break off from the rear end of migrating cancer cells.
- Extracellular vesicle
- A small membrane-bound sac that a cell releases outward.
- EMT
- Epithelial-mesenchymal transition; the cell’s shift to a more mobile state that is prone to spreading.
- ctDNA
- DNA fragments circulating in the blood that come from tumor cells.
- Liquid biopsy
- The general name for tests that look at tumor-derived material in fluids such as blood instead of tissue.
- Somatic mutation
- A gene change that is not inherited but acquired later and found only in tumor cells.
- WGS
- Whole-genome sequencing.
- ddPCR
- Droplet digital PCR; a method for counting a specific DNA change with very high sensitivity.
- OxPhos
- Oxidative phosphorylation; the main pathway of energy (ATP) production in mitochondria.
- 4T1
- A mouse breast cancer cell line; widely used in laboratory research.
Verified: The title of the paper, its online publication date (28 October 2026), its abstract and the numbers in its results were read from the Nature Cell Biology page; the institution of the study, its lead authors, the cell models and the statements about possible clinical effects were read from the press release of the MUHC Research Institute. Only mentioned: The full author list was cut off on the page; volume and issue information was not visible. The page we read ended in the middle of the discussion; we did not read the rest of the discussion, the additional data or the peer review reports. We did not look for an independent replication of the paper. Not verified and therefore not written: data showing that MoVes are present in human tumors or in patient blood; their causal role in the spread of cancer; the situation of access in Turkey; overlap with articles on drozdogan.com (not checked). Assessments and opinions belong to this article. This article is not medical advice; no diagnosis or treatment decision should be made based on it.
Who is this article for? Patients, their relatives and health professionals interested in cancer biology and liquid biopsy. Only the physicians who follow you can make decisions about your own situation.
References
- Tsering T, Nadeau A, Ghasemi M, et al. Motile vesicles (MoVes) are a cancer cell migration-associated extracellular vesicle population. Nature Cell Biology, published online 28 October 2026. DOI 10.1038/s41556-026-02097-2. nature.com
- MUHC Research Institute. Discovery of a potential new vehicle for cancer spread (press release, 28 October 2026). muhc.ca
Was this article helpful?
Your feedback helps us improve our content.
